8-KOther EventsExhibits & Filings

ELI LILLY & Co 8-K Report, Corporate Update (Feb 9, 2024)

Filed February 9, 2024For Securities:LLY

Summary

Eli Lilly and Company (LLY) announced on February 7, 2024, its successful issuance of $6.45 billion in aggregate principal amount of senior notes through an underwriting agreement with several major financial institutions. This offering comprised five tranches of notes with varying maturities ranging from 2027 to 2064 and coupon rates from 4.500% to 5.100%. The net proceeds from this significant debt issuance, totaling approximately $6.45 billion after deducting underwriting discounts, are expected to bolster Lilly's financial flexibility. This substantial capital raise indicates Lilly's strategic approach to financing its operations, research and development, and potential future growth initiatives. The diverse maturity profile of the notes allows for a structured approach to debt management. Investors should note that the company retains the option to redeem these notes under specific conditions, and the principal amount may become immediately due and payable in the event of a default, as outlined in the indenture agreement.

Key Highlights

  • 1Eli Lilly raised approximately $6.45 billion in net proceeds from the issuance of senior notes.
  • 2The offering included five series of notes with aggregate principal amounts totaling $6.45 billion.
  • 3Note maturities range from 2027 to 2064, with coupon rates between 4.500% and 5.100%.
  • 4The issuance was facilitated through an underwriting agreement with a syndicate of prominent investment banks.
  • 5The offering was registered under a Form S-3 registration statement, indicating prior SEC review.
  • 6The company has the option to redeem the notes, in whole or in part, under specified terms.
  • 7An Event of Default could lead to the acceleration of principal repayment for the notes.

Frequently Asked Questions

The filing does not explicitly state the use of proceeds for this debt issuance. However, such significant capital raises are typically used to fund ongoing operations, invest in research and development, support potential acquisitions, or manage existing debt obligations. Investors can infer that this strengthens Lilly's financial position to pursue its strategic objectives.

The notes issued have the following terms: 4.500% Notes due 2027, 4.500% Notes due 2029, 4.700% Notes due 2034, 5.000% Notes due 2054, and 5.100% Notes due 2064.

Eli Lilly raised approximately $6.45 billion in net proceeds after deducting underwriting discounts and before estimated offering expenses.

A Form S-3 registration statement allows well-known seasoned issuers like Eli Lilly to register securities offerings efficiently. It indicates that the company has met certain SEC reporting requirements and provides a framework for future, similar offerings.